Ginkgo Bioworks Holdings (DNA) Capital Expenditures (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Capital Expenditures came in at -$94000.0 in Q1 2026, down 101.23% YoY from $7.6 million in Q1 2025, and down 1980.0% on a QoQ basis from $5000.0 in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Capital Expenditures (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Capital Expenditures data on file, last reported at -$94000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 101.23% year-over-year to -$94000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51000.0 (down 100.08% YoY) and the FY2025 annual result came in at $7.7 million, down 87.74% from the prior year.
- Capital Expenditures slipped to -$94000.0 in Q1 2026, from $5000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $62.3 million in Q4 2024 to a low of -$30.2 million in Q3 2023.
- A 5-year average of $9.6 million and a median of $6.7 million in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures slumped 415.64% — and 2025, when it surged 1282.89%.
- Tracing DNA's Capital Expenditures over 5 years: stood at $42.3 million in 2022, then slipped by 9.94% to $38.1 million in 2023, then soared by 63.77% to $62.3 million in 2024, then tumbled by 99.99% to $5000.0 in 2025, then tumbled by 1980.0% to -$94000.0 in 2026.
- The last three Capital Expenditures figures came in at -$94000.0 (Q1 2026), $5000.0 (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 2.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.62 Mn |
| Jun 30, 2026 | 2.62 Mn |
| Mar 31, 2026 | -94,000.00 |
| Mar 31, 2026 | -94,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 7.54 Mn |
| Sep 30, 2025 | 7.54 Mn |
| Jun 30, 2025 | -7.50 Mn |
| Jun 30, 2025 | -7.50 Mn |
| Mar 31, 2025 | 7.62 Mn |
| Mar 31, 2025 | 7.62 Mn |
| Dec 31, 2024 | 62.35 Mn |
| Dec 31, 2024 | 62.35 Mn |
| Sep 30, 2024 | -637,000.00 |
| Sep 30, 2024 | -637,000.00 |
| Jun 30, 2024 | -5.88 Mn |
| Jun 30, 2024 | -5.88 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Mar 31, 2024 | 6.71 Mn |